On October 30, 2025 Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, reported that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in fireside chats at the following investor conferences in November.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Stifel 2025 Healthcare Conference, New York, NY
Thursday, November 13, 2025, from 9:20 – 9:50 a.m. ET
Jefferies Global Healthcare Conference – London, UK
Wednesday, November 19, 2025, from 11:00 – 11:25 a.m. GMT
The fireside chats will be webcast live and can be accessed via a link in the Investors section of the Nurix website. The archived webcasts will be available for 30 days after the event.
(Press release, Nurix Therapeutics, OCT 30, 2025, View Source [SID1234657168])